ANTIBODY-INDUCING POLYPEPTIDE AND VACCINE
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Oct 31, 2024
app pub date -
Jun 24, 2022
filing date -
Jun 24, 2022
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
An antibody-inducing polypeptide useful for treatment or prevention of SARS-COV-2 infection and a vaccine including the same are disclosed. The polypeptide can be (a) one having 7 or more continuous amino acids in a region of positions 336 to 361, 406 to 432, or 446 to 480 of SEQ ID NO: 1, (b) one having an amino acid sequence with 80% or higher sequence identity to the amino acid sequence of any polypeptide in (a), (c) one including the polypeptide defined in (a) or (b) as a partial sequence and no region other than the partial sequence of SEQ ID NO: 1, (d) one having 10 or more continuous amino acids in a region of positions 1144 to 1161 or 1174 to 1202 of SEQ ID NO: 1, (c) one with an amino acid sequence having 80% or higher sequence identity to the amino acid sequence of any polypeptide in (d) or (f) one including the polypeptide in (d) or (e) as a partial sequence and no region other than the partial sequence of SEQ ID NO: 1.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully